and various other countries.
2013. It is now licensed in the USA, Canada, Europe, Australia
extensiveclinicalassessment23,andwas firstapprovedbyFDAi
filtration for storage and formulation22. RIV4 has undergon
using tangential flow filtration and passed through steril
brane filtration. Purified rHA is suspended in relevant buffe
extract using column chromatographies followed by Q mem
extracted using detergent and purified from the clarified cel
polyhedrin promotor. rHA molecules from the infected cells ar
genes, which are expressed under the control of a baculoviru
recombinant baculovirus carrying the relevant influenza H
(BEVS)22. In brief, expresSF+ insect cells are infected wit
in insect cells using a baculovirus expression vector syste
productionplatforminwhichrecombinantHA(rHA)isexpresse
the four strains. The production of RIV4 is based on a nove
unadjuvantedvaccinecontaining45µgofHA/dosefromeacho
(as for inactivated split-virion and subunit vaccines). RIV4 is a
viralproteinsinsteadofantigensderivedfromliveinfluenzaviru
licensed influenza vaccine to be produced using recombinan
Flublok®, Supemtek® [EU, Canada], Sanofi Pasteur) was the firs
timelines.Therecombinantquadrivalentinfluenzavaccine(RIV4
producenew,effectivevaccineswithinaccelerateddevelopmen
demonstrated the feasibility of using more efficient methods t
in the urgent response to the COVID-19 pandemic ha
(including mRNA, vector, and recombinant protein strategies
adoption of alternative vaccine development approache
avian flu pandemics, when egg supply may be impacted. Th
delivery for upcoming epidemic seasons and during potentia
manufacture of influenza vaccines are needed to ensure timel
and egg-free technologies allowing for guaranteed and faste